Aug 2026· Expert Opinion on Drug Delivery· pp. 1-19· 0 citations· 138 references
Medicine
TL;DR
A pathology-driven microenvironment-adaptive framework is proposed and the limitations of current delivery strategies are critically evaluated, followed by a discussion of how molecular building blocks and delivery platforms can be engineered to realize microenvironment-adaptive therapeutic strategies.
Abstract
INTRODUCTION
Ulcerative colitis (UC) is characterized by recurrent, chronic, and nonspecific intestinal inflammation. It is strongly associated with an increased risk of colorectal cancer, representing a global public health challenge. However, the complex pathological microenvironment of UC, characterized by mucus barrier disruption, increased epithelial permeability, immune dysregulation, and oxidative stress, substantially compromises the therapeutic efficacy of conventional drugs.
AREAS COVERED
Nanomedicine delivery systems have offered new opportunities for UC treatment, these systems can optimize drug transport, distribution, and controlled release, thereby better addressing the therapeutic requirements of UC. Relevant literature was identified through PubMed, with a primary focus on studies published between January 2016 and August 2026.
EXPERT OPINION
The fundamental relationship between disease pathology and delivery system design remains insufficiently explored. To address this gap, this review proposes a pathology-driven microenvironment-adaptive framework and critically evaluates the limitations of current delivery strategies. We translate the key pathological barriers into actionable design criteria, followed by a discussion of how molecular building blocks and delivery platforms can be engineered to realize microenvironment-adaptive therapeutic strategies. This review provides insights and new perspectives for the rational design of microenvironment-adaptive systems for UC.
Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, serves as a compelling model for advanced drug delivery innovation owing to its well-characterised inflammatory microenvironment and significant unmet clinical need. This semi-systematic review evaluated three converging innovation s...
Saravanakumar Parameswaran, Satheesh Babu Natarajan, Nivetha Shanmugam et al.· International Journal of App...· 0 citations
Abstract Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disorder with a complex etiology and a high recurrence rate. Conventional treatments face significant limitations in targeting, stability, and efficacy. Going beyond conventional reviews that focus on isolated mechanisms, this review offers...
Jun-Hui Qian, Si-Qi Shen, Si-Jia Chen et al.· International Journal of Nan...· 0 citations
Abstract Colon-targeted drug delivery systems (CTDDS) are a current focus in the medical field, as they directly target the colon, enabling better management of diseases such as ulcerative colitis (UC), Crohn’s disease (CD), inflammatory bowel disease (IBD), and colorectal cancer (CRC) with minimal side effects. This s...
Ekta Rathore, Nidhi Agrawal, Mohammad Akbar Siddiqui et al.· International Journal of Pol...· 0 citations
Digestive diseases, including inflammatory bowel disease (IBD), gastrointestinal mucosal injury, colorectal cancer-associated inflammation, peptic ulcer disease, and postoperative gastrointestinal complications, are increasingly understood as disorders of a dynamic and spatially heterogeneous microenvironment rather th...
Lin-Ying Peng, Xue-Yan Jia, Huan Chen et al.· Frontiers in Bioengineering...· 0 citations
To overcome biopharmaceutical bottlenecks, an overview of nanozyme-based intelligent delivery platforms tailored for the inflamed gut are provided, covering endogenous/exogenous stimuli-responsive, biomimetic, and microbiota-mediated systems.
The treatment of inflammatory skin diseases poses significant challenges due to the complex
Inflammatory Microenvironment (IME) and inherent limitations of the skin barrier. However,
given its dynamic nature and pivotal involvement in disease pathogenesis, the IME represents an
ideal target for precision interventi...
Yang-Yang Zhang, Jun-Kun Qu, Yu-Ling Chen et al.· Current Drug Delivery· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.